View source for 18464360. C-RAF Mutants that Confer Resistance to RAF Inhibitors simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)

=C-RAF Mutants that Confer Resistance to RAF Inhibitors=


==Organization Name==

[[:Category:DANA-FARBER CANCER INSTITUTE, INC.|DANA-FARBER CANCER INSTITUTE, INC.]]


[[Category:DANA-FARBER CANCER INSTITUTE, INC.]]

==Inventor(s)==

[[:Category:Caroline Emery of Kansas City MO (US)|Caroline Emery of Kansas City MO (US)]][[Category:Caroline Emery of Kansas City MO (US)]]

[[:Category:Rajee Antony of Norwood MA (US)|Rajee Antony of Norwood MA (US)]][[Category:Rajee Antony of Norwood MA (US)]]

[[:Category:Levi A. Garraway of Newton MA (US)|Levi A. Garraway of Newton MA (US)]][[Category:Levi A. Garraway of Newton MA (US)]]

==C-RAF Mutants that Confer Resistance to RAF Inhibitors - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18464360 titled 'C-RAF Mutants that Confer Resistance to RAF Inhibitors

==Simplified Explanation==

The patent application describes nucleic acids and proteins with a mutant C-RAF sequence for identifying cancer patients who may benefit from combination therapy.

* Mutant C-RAF sequence in nucleic acids and proteins
* Methods for identifying cancer patients suitable for combination therapy
* Methods for treatment

== Potential Applications ==
The technology can be applied in:
* Personalized medicine
* Cancer treatment

== Problems Solved ==
The technology helps in:
* Identifying patients who will benefit from combination therapy
* Tailoring treatment to individual patients

== Benefits ==
The benefits of this technology include:
* Improved treatment outcomes
* Reduced side effects from unnecessary therapies

== Potential Commercial Applications ==
The technology can be commercially applied in:
* Pharmaceutical companies
* Biotechnology firms

== Possible Prior Art ==
Prior art may include:
* Previous patents on cancer treatment methods
* Research articles on C-RAF mutations in cancer

== Unanswered Questions ==

=== How does the mutant C-RAF sequence impact cancer treatment outcomes? ===
The patent application does not delve into the specific mechanisms by which the mutant C-RAF sequence affects treatment outcomes.

=== Are there any potential side effects associated with using this technology? ===
The patent application does not address any potential side effects that may arise from utilizing this technology.


==Original Abstract Submitted==

Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.



[[Category:C12Q1/6886]]
[[Category:C12N9/12]]